Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK. Leach MO, et al. Among authors: jayson gc. Br J Cancer. 2005 May 9;92(9):1599-610. doi: 10.1038/sj.bjc.6602550. Br J Cancer. 2005. PMID: 15870830 Free PMC article.
Chemotherapy for ovarian cancer--a consensus statement on standard practice.
Adams M, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM. Adams M, et al. Among authors: jayson gc. Br J Cancer. 1998 Dec;78(11):1404-6. doi: 10.1038/bjc.1998.699. Br J Cancer. 1998. PMID: 9836470 Free PMC article. No abstract available.
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.
Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC. Ton NC, et al. Among authors: jayson gc. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. doi: 10.1158/1078-0432.CCR-07-1550. Clin Cancer Res. 2007. PMID: 18056191 Clinical Trial.
Antiangiogenic drugs in ovarian cancer.
Kumaran GC, Jayson GC, Clamp AR. Kumaran GC, et al. Among authors: jayson gc. Br J Cancer. 2009 Jan 13;100(1):1-7. doi: 10.1038/sj.bjc.6604767. Epub 2008 Nov 11. Br J Cancer. 2009. PMID: 19002176 Free PMC article. Review.
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
Mitchell CL, O'Connor JPB, Jackson A, Parker GJM, Roberts C, Watson Y, Cheung S, Davies K, Buonaccorsi GA, Clamp AR, Hasan J, Byrd L, Backen A, Dive C, Jayson GC. Mitchell CL, et al. Among authors: jayson gc. Ann Oncol. 2010 Oct;21(10):1982-1989. doi: 10.1093/annonc/mdq079. Epub 2010 Mar 29. Ann Oncol. 2010. PMID: 20351070 Free article.
188 results